why choose us

First received: April 08, 2024

Clinical Trial: Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Major Depressive Disorder

Study Type: INTERVENTIONAL


Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Solriamfetol in Subjects With Major Depressive Disorder

Brief Summary: PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the safety and efficacy of solriamfetol for the treatment of major depressive disorder (MDD) in adults.

Read more